Novel combination therapy for non-Hodgkin lymphoma in people and dogs
Official title: Translation of a novel combination therapy approach for non-Hodgkin lymphoma
Funded at Mayo Clinic Rochester · NIH-11473229 · Data updated 2026-11-12
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $67,413 |
| NIH project number | 3U01CA272257-05S1 |
| Project ID | NIH-11473229 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with relapsed or refractory non-Hodgkin lymphoma, including DLBCL, who can participate in translational studies and potential clinical evaluations.
✕Less likely to help
Patients with NHL who cannot tolerate the proposed combination or have contraindications to the investigational therapy may not benefit.
What this research studies
This grant focuses on translating a promising therapy for advanced non-Hodgkin lymphoma (NHL) by testing a novel combination that may boost immune responses and overcome treatment resistance. The work spans human patients and canine lymphoma models to mirror real-world disease and treatment effects. Researchers will study how the therapy behaves in the body, its safety, and how it interacts with existing chemotherapy and immune therapies, aiming to improve outcomes for those with relapsed or refractory NHL. The Mayo Clinic team led by Shruthi Naik will integrate preclinical findings with early clinical observations to guide further development.
Why it matters
Potential benefit: If successful, patients with relapsed or refractory NHL could experience better responses and longer control of the disease.
How similar studies have gone: Previous NHL immunotherapy approaches show limited efficacy, but combining therapies in realistic canine and human models is a novel approach with preliminary promise.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Naik, Shruthi — Mayo Clinic Rochester
- Study coordinator: Naik, Shruthi
Related research
Other NIH-funded projects on the same topics.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
Precision targeted radioactive antibody therapy for non-Hodgkin lymphoma
Researchers are developing more precise radioactive antibodies to treat people with CD20-positive non-Hodgkin lymphoma.
-
AI-designed drugs targeting a common lymphoma mutation (MYD88 L265P)
Researchers are using artificial intelligence to create and test new drugs that block a common MYD88 mutation found in many B‑cell non‑Hodgkin lymphomas to help people with these cancers.
-
New combination therapy for non-Hodgkin lymphoma
A virus-based combination treatment aims to boost the immune system to help people and companion dogs with relapsed or treatment-resistant diffuse large B-cell lymphoma.
-
New combination treatment for diffuse large B‑cell lymphoma
This project is trying a virus-based therapy together with checkpoint immunotherapy for people (and companion dogs) with relapsed diffuse large B‑cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.